000			03093nam a22003615i 4500
999			_c80443 _d80443 _x1
001			80443
003			ES-MaUEC
005			20230207040305.0
006			a||||fo|||| 00| 0
007			cr nn 008mamaa
008			141106s2014 gw | s |||| 0|eng d
020			_a9783319083506
024	7		_a10.1007/978-3-319-08350-6 _2doi
040			_aES-MaUEC _bspa _cES-MaUEC _dES-MaUEC
050		4	_aRC643 _b2014 EB
100	1		_aHughes, Timothy P. _988622 _0Local
245	1	0	_aHandbook of Chronic Myeloid Leukemia _cby Timothy P Hughes, David M Ross, Junia V Melo.
264		1	_aCham _bSpringer International Publishing _bImprint: Adis _c2014.
300			_a1 recurso en línea (XIII, 65 p.) _b14 ilustraciones, 12 ilustraciones en color
336			_aTexto _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
505	0		_aEpidemiology and risk factors.-Â{u0874}hophysiology.-Diagnosis -- Management of patients with CML -- Challenges of treatment: treatment-resistant CML -- Useful resources for your patients and caregivers.
520			_aThis concise, clinically focused pocket handbook assembles and synthesizes the latest developments and trends in the diagnosis and treatment of CML and provides an authoritative and convenient summary of the latest progress in TKI trials, the molecular monitoring of CML responses, and the development of new therapies to overcome resistance and improve patient care. Chronic myeloid leukemia (CML) is a rare type of leukemia (1â€{u2830}er 100,000 people) but is the most common chronic myeloproliferative neoplasm. CML remains a key model for the improved understanding of the pathophysiology of a malignancy at a molecular level; CML was the first cancer to be associated with a recurring chromosome abnormality,Â{u7A29}ch generates the Philadelphia (Ph) chromosome and its associated fusion gene BCR-ABL1.Â{u4A25} clinical outcome for patients with CML has changed dramatically in the past 15 years andÂ{u4A29}s has been due to the development of tyrosine kinase inhibitors (TKIs), compounds that inhibit the activity of the oncogenic BCR-ABL1 protein.Â{u182E}number of first-, second- and third-generation TKIs are now available for theÂ{u4CA5}atment of CML, although a number of treatment challenges remain, not least the development of treatment-resistant CML.Â{u0872}allel to the development of specific drugs for treating CML, major advances have been made in the field of disease monitoring and standardization of response criteria.Â{uE000}
988			_aEBOOK, EBSPRINGER
650		7	_9676045 _aLeucemia mieloide crónica _2embne
700	1		_aRoss, David M. _0Local _eautor _988623
700	1		_aMelo, Junia V. _988624 _0Local _eautor
710	2		_aSpringerLink (Online service) _0Local _9106996
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://link.springer.com/book/10.1007/978-3-319-08350-6 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
942			_2lcc _cLE
998			_b10/2020 _dz _eIG _feng _ggw _h0